CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 73 enrolled
Drug / intervention
Atropine +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00944710
NCT00944710Phase 3Completed

Augmenting Atropine Treatment for Amblyopia in Children 3 to < 8 Years Old

Jaeb Center for Health Research·interventional·Posted Jul 23, 2009·Updated Mar 6, 2019

In Brief

A Phase 3 clinical trial evaluating Atropine and Plano lens for Amblyopia. Completed, enrolled 73 participants across 2 sites.

Detailed Summary

This study is designed to evaluate the effectiveness of adding a plano lens to weekend atropine after visual acuity has stabilized with weekend atropine but amblyopia is still present. Children ages 3 to \<8 years with visual acuity of 20/50 to 20/400 in the amblyopic eye will be enrolled in a run-in phase with weekend atropine until no improvement, followed by randomization of eligible patients to weekend atropine treatment with a plano lens over the sound eye versus without a plano lens over the sound eye. The primary objective is to determine if adding a plano lens to weekend atropine will improve visual acuity in patients with amblyopia still present after visual acuity has stabilized with initial treatment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAmblyopia
CountriesUnited States

Timeline

Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedJul 23, 2009
Enrollment StartAug 1, 2009
Primary CompletionOct 1, 2013
Study CompletionNov 1, 2013
TodayJul 2, 2026
Enrollment to primary: 4.2 yearsPosted 16.9 years ago

Interventions

Atropinedrug

Weekend atropine 1%

Plano lensdevice

plano lens over the sound eye

Atropinedrug

Weekend atropine 1%